Review

TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?

Thomas Benoot †, Elisa Piccioni †, Kirsten De Ridder ‡ and Cleo Goyvaerts *

Abstract: Tumor necrosis factor-alpha (TNFα) can bind two distinct receptors (TNFR1/2). The transmembrane form (tmTNFα) preferentially binds to TNFR2. Upon tmTNFα cleavage by the TNF-alpha-converting enzyme (TACE), its soluble (sTNFα) form is released with higher affinity for TNFR1. This assortment empowers TNFα with a plethora of opposing roles in the processes of tumor cell survival (and apoptosis) and anti-tumor immune stimulation (and suppression), in addition to angiogenesis and metastases. Its functions and biomarker potential to predict cancer progression and response to immunotherapy are reviewed here, with a focus on lung cancer. By mining existing sequencing data, we further demonstrate that the expression levels of TNFα and TACE are significantly decreased in lung adenocarcinoma patients, while the TNFR1/TNFα2 balance is increased. We conclude that the biomarker potential of TNFα alone will most likely not provide conclusive findings, but that TACE could have a key role along with the delicate balance of sTNFα/tmTNFα as well as TNFR1/TNFα2, hence stressing the importance of more research into the potential of rationalized treatments that combine TNFα pathway modulators with immunotherapy for lung cancer patients.

Keywords: TNFα; TNFR1; TNFR2; lung cancer; immunotherapy; immune checkpoint inhibition (Min. 5–Max. 8)

1. The Pleiotropic Immunological Biology of TNFα

About 60 years ago, it was reported that bacterial endotoxin administration to mice resulted in the release of a serological protein with necrotic anti-tumor activity at high concentrations. Due to the latter characteristic, this protein was termed tumor necrosis factor (TNF) [1] and considered a breakthrough for cancer therapy. Today, the TNF superfamily consists of 19 members and 29 TNF receptors [2]. Within this family, functional TNFα is represented by a trimer of 17.35 kDa monomers, folded into a rigid bell-shaped “jelly roll” composed of antiparallel filaments [3]. It exists in two forms: a transmembrane form (tmTNFα) next to a soluble (sTNFα) form. The latter one is cleaved from tmTNFα by the metalloproteinase TNF-alpha-converting enzyme (TACE). Upon X-ray crystallography analysis, TNFα was demonstrated to bind to TNF receptors 1 and 2 (TNFR1 and TNFR2), represented by a 55 and 75 kDa type I and type II transmembrane protein, respectively [4,5]. The structural pleiotropism of TNFα and its receptors endows it with a multifaceted role linked to both anti- and pro-inflammatory assets as well as apoptotic assets. The complexity of these findings tempered the original enthusiasm for TNFα as a breakthrough molecule for cancer therapy.

1.1. The Pro-Inflammatory Character of sTNFα versus tmTNFα

Soluble TNFα is mainly secreted by activated macrophages [6] and to a lesser extent, by T lymphocytes, natural killer (NK) cells, neutrophils, endothelial and cardiac muscle cells, fibroblasts, and osteoclasts [7,8]. By comparison, tmTNFα is expressed constitutively on the...
surface of a broad range of immune cells such as alveolar and non-alveolar macrophages [9], monocytes [10], lymphocytes [11], dendritic cells (DCs), and NK cells [12]. In addition, its expression has been reported on non-immune cells such as adipocytes [13] and tumor cells [14].

In general, sTNFα is rapidly released upon trauma or infection, as it is bestowed with a determining role in immunoregulatory processes such as immune ontogeny, inflammation, and apoptosis [7]. As a soluble pro-inflammatory cytokine, it primarily acts at sites remote from the TNFα-producing cells to support the production of downstream pro-inflammatory cytokines along with the recruitment, activation, and regulation of inflammatory cells such as macrophages. To illustrate, when macrophages are activated by Toll-like receptors, they secrete sTNFα, which subsequently regulates macrophage differentiation in an autocrine fashion [15]. Hence, TNFα neutralizing antibodies have been shown to reduce the production of several pro-inflammatory cytokines and growth factors such as interleukin-1 (IL-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [16]. Of note, sTNFα has an intrinsic pleiotropic activity as it is also involved in anti-inflammatory responses that aim to restore homeostasis [17].

In comparison, tmTNFα is an important mediator of immune-cell crosstalk. To illustrate, when DCs express tmTNFα, the latter can interact with TNFFR2 on NK cells, resulting in increased NK cell proliferation and cytotoxic activity [18]. Moreover, tmTNFα can act in a dual manner upon its interaction with TNFRI: either as a ligand or as a receptor through an “outside-to-inside” signaling pathway known as “reverse signaling”. There is evidence that, as a ligand, it is mainly involved in host defense mechanisms against infections [19], while the receptor-like form appears to have a role in modulating immune cell activation. To elaborate, tmTNFα expressed by activated T cells can bind to TNFRI2, expressed by monocytes, leading to monocyte activation with subsequent secretion of interleukin-10 (IL-10) and sTNFα. Additionally, endogenous IL-10 was shown to downregulate T cell contact-mediated sTNFα production by monocytes, suggestive for an autoregulatory loop involving both sTNFα and tmTNFα [19–21]. What is more, T cells can also activate monocytes by expressing TNFRI2 that can trigger reverse signaling via tmTNFα, expressed by the monocytes. Hence, both TNFα isoforms are significantly involved in the regulation of the inflammatory response [22].

1.2. Two Distinct Receptors Fine-Tune TNFα’s Biological Effects

TNFRI, also known as tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) or CD120a, is expressed on almost all host cells including various tumor cell types [23–26] and tumor-associated endothelial cells [27]. In contrast, TNFRI2 (TNFRSF1B or CD120b) is predominantly located on the surface of immune cells, such as NK cells, macrophages [28], regulatory T cells (Tregs), suppressive myeloid cells [29], and endothelial cells [30]. As indicated by “+” in Figure 1, sTNFα shows a significantly higher affinity for TNFRI1 than tmTNFα, while the opposite holds true for TNFRI2 [31,32].

In terms of biological effects, high affinity binding to TNFRI1 (and not TNFRI2) has been demonstrated to result in DC activation and subsequent stimulation of antigen specific CD8+ T cells [33]. That TNFRI1-knockout (ko) mice show resistance to colitis development [34] further confirms its involvement in the differentiation of inflammatory T cells. In comparison, activation of TNFRI2 in lymphoid cells leads to inflammatory responses as well as T cell activation, thymocyte proliferation, GM-CSF production [7], and NK cell-mediated IFN-γ production [35]. Yet, its main role seems to be linked to restoration of homeostasis and promotion of an immunosuppressive environment, as TNFRI2 gene ko models show elevated inflammatory responses [33,34,36]. To illustrate, TNFRI2 signaling has been shown to promote Treg differentiation, proliferation, and suppressive function, while TNFRI1 does not affect Treg cell expansion [37–39]. Moreover, upon activation of both TNFRs, TNFRI2 is more liable to receptor shedding than TNFRI1 [40–42]. The shedded soluble TNFRs have been shown to serve as decoy receptors for sTNFα to control its innate immune activation threshold. Hence, more pronounced TNFRI2 shedding is in line with its immune restorative function [43,44].
Next to their roles in immune cell proliferation and activation, triggered TNFR1 and TNFR2 can also induce apoptotic and necrotic cell death. In the case of TNFR1, this is the result of the interaction between the receptors’ death domain (DD) and the adapter protein TNF receptor-associated death domain (TRADD). Upon interaction of DD-TRADD, the activation of cysteine-aspartyl-specific proteases (caspases) is stimulated [45,46]. Although TNFR2 lacks a DD, it has been reported to cause activation-induced cell death (AICD), e.g., in mature CD8+ T cells [36]. As outlined in Figure 1, the different outcomes upon TNFR1 and 2 triggering result from their distinct downstream signaling [47]. Although both exploit the NF-κB pathway for transcriptional activation of inflammatory and anti-apoptotic genes [48], the “classical” NF-κB pathway is mainly activated upon sTNFα binding to TNFR1 [31], while the “alternative pathway” is preferentially but not exclusively primed upon TNFR2 binding [28,49,50]. Additionally, both TNFRs can regulate gene expression by activating at least two members of the MAP kinase (MAPK) family, such as P38 [51,52] and JNK [53], and this via a series of protein phosphorylations (MEKK). Notably, the TNF superfamily member lymphotoxin alpha can, in its soluble homotrimer form (LTα3), also bind to both TNFRs with an affinity profile comparable to that of sTNFα [54,55]. In terms of biological effects, sTNFα and LTα3 have been reported to show equal mitogenic stimulation capacities upon TNFR binding, yet sTNFα was shown to be more potent to mediate gene regulation and cytotoxicity.

Figure 1. Pathways activated by soluble TNFα (sTNFα) and transmembrane TNFα (tmTNFα) upon binding to TNFRs. Downstream signaling via TNFR1 is most effective upon high-affinity (+++) binding to sTNFα. In the case of TNFR1, this can lead to caspase8/3-mediated apoptosis through signaling via its death domain (DD), recruitment of TRADD, and subsequent recruitment of FADD or TRAF2. The latter could also result in activation of pro-inflammatory signals via the "classical NF-κB” pathway, and is primarily activated via TNFR1 (red arrows). Upon high-affinity (+++) binding of tmTNFα to TNFR2, TRAF2 is triggered, which preferentially results in NF-κB activation via the alternative pathway (blue arrows) to activate the expression of proliferation and survival related genes.
Both sTNFα and tmTNFα bind with low-affinity (+) to TNFR2 and TNFR1 respectively. TNF-alpha-converting enzyme (TACE), responsible for the conversion of sTNFα from tmTNFα and of soluble TNFRs [56]. For completeness, the alternative TNFR ligand lymphotoxin alpha 3 (LTα3), with its affinity binding profile to TNFR1 and 2, is depicted as well. This figure was created with BioRender.com (accessed on 4 June 2021).

In conclusion, the presence of two functional isoforms (soluble and transmembrane) next to two receptors with specific expression, affinity, and downstream signaling avenues collectively serves the pleiotropic job description of TNFα. As regulator of cytotoxic, pro-, and anti-inflammatory functions, it is evident that TNFα can play a critical role in the development of chronic inflammatory diseases as well as cancer, as outlined below.

2. TNFα Plays Opposing Roles in Cancer

Despite TNFα’s denomination, in vitro reported tumor necrosis after high TNFα concentrations appeared a phenomenon that is not so straightforwardly translated to successful cancer treatments in vivo. The latter is partly explained by TNFα’s multifunctionality as a cytotoxic but also immune modulating cytokine. As the immune system plays a complex role on the tumor microenvironmental (TME) battlefield, TNFα is used as a weapon to modulate and/or kill tumor cells, immune cells, and/or endothelial cells [57].

Previously observed direct anti-tumoral properties of TNFα in vivo are among others based on its capacity to hinder tumor-associated blood vessel formation (angiogenesis) via selective endothelial cytotoxicity and necrotic hemorrhage [58]. This selective endothelial cytotoxicity can subsequently result in hyperpermeability of tumor vessels and increased blood cell extravasation. The exact underlying mechanism remains unknown, yet van Horssen et al. [59] described the noteworthy hypothesis that tumor-residing endothelial cells are more sensitive to TNFα because they upregulate TNFR1 upon cytokine signaling by tumor cells and macrophages. However, external administration of TNFα was shown to occupy TNFR1 expressed by tumor and healthy endothelial cells without toxicity towards the latter, due to the presence of a low number of receptors on healthy cells [60]. Nevertheless, studies in mice and rats further showed a synergistic anti-tumor effect of TNFα in combination with chemotherapeutic drugs, as accumulation of the latter at the tumor site was shown to be improved [61–63]. Moreover, persistent high-level stimulation with TNFα in vitro inhibits endothelial cell proliferation in a dose-dependent manner [64], further supporting its anti-angiogenic effects [65–67]. However, Fajardo et al. hypothesized that TNFα could show both pro- and anti-angiogenic effects in vivo, depending on its local concentration. When murine TNFα was administered subcutaneously in mice, this was shown to exert opposing effects. At low doses (range: 0.01–1 ng), TNFα induced angiogenesis whereas increasing doses (1 and 5 µg) reduced this effect with complete abolishment at the highest doses [68].

While a high concentration of TNFα has been linked to hemorrhagic necrosis, it is now widely accepted that chronic exposure to TNFα is more likely to promote tumor progression. First, it has been demonstrated repeatedly that chronic inflammation, in which the innate immune system plays a leading role, can promote cancer onset as well as progression and metastasis, typifying the “never-healing-wound” character of solid cancers [69,70]. Indeed, chronic exposure to TNFα can promote cellular transformation via the induction of direct mutations and DNA damage [71] as well as via profound epigenetic changes that modulate the expression level of oncogenes and tumor suppressor genes [72]. In addition, inflammation influences epithelial-to-mesenchymal cell transition (EMT) and subsequent cancer cell invasion. Further, TNFα has been shown to affect expression of EMT-inducing transcription factors, particularly in synergy with TGFβ [73]. Moreover, TNFα associated with chronic inflammation can be held responsible for the observed phenomenon of cancer cell specific resistance to TNFα-induced cell death [74]. Specifically, chronic TNFα/TNFR1 binding increases the expression of anti-apoptotic, angiogenic, and invasive proteins via the TAK-1, MAPKs, Akt, IKK, AP-1, and NF-κB signaling pathways [28,75,76]. Notably, also
the ligands and receptors of the LTα family with, among others, affinity for TNFR1 and 2, have been linked to increased carcinogenesis, as extensively reviewed elsewhere [55,77].

Even if chronic inflammation is not involved in the onset of tumor cell transformation, the immune system often becomes a co-worker during cancer progression. Today it is generally accepted that the immune system can identify and control nascent malignancies in a process called cancer immunosurveillance. In contrast, the latter can also promote tumor progression through the selection of poorly immunogenic variants and suppression of anti-tumor immunity. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting and comprise three distinct phases: the elimination, equilibrium, and escape phase [78–80].

The elimination phase is characterized by an imbalance towards more anti-tumor immunity, installed by adaptive as well as innate immune cells. Characteristic for a potent Th1-oriented tumor-associated antigen (TAA) specific adaptive immune response is the presence of immunogenic TAAs, presented via MHC-I on the surface of tumor cells, together with Fas, TRAIL, and IFN-γ receptors and the presence of perforin, granzymes, IFN-α/β/γ, IL-1, IL-12, and TNFα within the TME. Hence, TNFα can ameliorate this phase through its involvement in activation of T cells, macrophages, and NK cells. For example, it was shown that TNFR1 signaling promotes the accumulation of anti-tumor M1 polarized tumor-associated macrophages (TAMs) by suppressing the M2-polarizing release of IL-13 from eosinophils co-recruited with inflammatory monocytes [81]. On their turn, MHC-II-high (M1) TAMs and granulocytes can secrete, among others, TNFα, IL-1, and IL-12 to further ameliorate a Th1-polarized anti-tumor immune profile [82].

During the equilibrium phase, anti- and pro-tumor immunity are in balance and/or immune-mediated tumor dormancy is installed [80]. It was reported that the absence of TNFR or IFN-γ promoted angiogenesis and multistage carcinogenesis in an experimentally induced pancreatic murine tumor model, suggesting that a coordinated interaction between IFN-γ and TNFα was responsible for the activation of TAA-specific cytotoxic T cells [83]. Moreover, the combination of IFN-γ and TNFα drove pancreatic tumor cells into STAT-1 and TNFR1-mediated senescence [82]. Because IFN-γ and TNFα induce senescence in numerous murine and human cancers, this may be a general mechanism for arresting cancer progression.

In the escape phase, TNFα has several effects capable of lowering the antitumor immune response by facilitating the accumulation and/or activation of a wide range of immunosuppressive cells such as Tregs [37], regulatory B cells [84], and suppressive myeloid cells [85]. As stated before, the common factor of these immunosuppressive effects lies within TNFα binding to TNFR2. When secreted by activated CD4+ T-cells, TNFα has been shown to induce myelopoesis in tumor-bearing mice. Furthermore, cells of the myeloid lineage can be recruited to become immune-suppressive regulatory myeloid cells, which decrease TAA-specific CD8+ T cell mediated tumor cytotoxicity [86]. Moreover, it has been reported that tmTNFα, rather than sTNFα, is able to activate immunosuppressive myeloid cells upon binding to TNFR2. To illustrate, a marked increase in immunosuppressive myeloid cell accumulation was only observed when tmTNFα was constitutively expressed on 4T1 mammary tumor cells, with subsequent promotion of NO, ROS, IL-10, and TGF-β secretion by these myeloid cells and inhibition of lymphocyte proliferation. In contrast, 4T1 overexpression of sTNFα resulted in increased lymphocyte infiltration and tumor regression [87]. TNFα also facilitates the installment of an effector T cell hostile milieu via indoleamine 2,3-dioxygenase 1 (IDO1) accumulation in the TME. To illustrate, while M2b polarized macrophage conditioned medium stimulates tumor cell proliferation and IDO1 expression in vitro, this is reduced upon TNFα neutralization [88]. As IDO1 converts tryptophan to kynurenine, tryptophan is deprived with subsequent installment of TAA-specific T cell anergy, while Treg activity, lymphangiogenesis, and neovascularization are enhanced in vivo. Finally, TNFα has been linked to cancer therapy resistance. To illustrate, in a murine triple-negative breast cancer model, resistance to the anti-angiogenic drug bevacizumab was shown to be accompanied by M2b TAM-mediated secretion of
the chemokine CCL1 along with TNFα. Upon TNFα-neutralizing nanobody administration in vivo, this immunosuppressive M2b macrophage-induced resistance was overcome, supporting TNFα’s key role in resistance to bevacizumab [88].

Although both TNFα and its receptors’ precise role within the complex and ever-evolving TME are far from fully understood, substantial evidence has emerged that TNFα signaling has a paradoxical and dual role in cancer progression and the dynamic immunoediting process. While it has been held responsible for key tumor promoting features such as the maintenance of an antigen-ignorant chronic inflammatory state and immunosuppressive effects that hinder TAA-specific effector functions, its documented anti-tumor assets in vitro and in vivo hamper a clear-cut conclusion.

3. Specificities of TNFα in Lung Cancer Progression

Lung cancer remains the leading cause of cancer-related deaths worldwide, responsible for almost 1.8 million deaths in 2020 alone [89]. Lung cancer comprises two key types: non-small cell lung cancer (NSCLC), accounting for 80–85% of cases, and small cell lung cancer (SCLC) [90].

As the human respiratory tract is continuously exposed to air that can potentially contain airborne pathogens, lungs necessitate a unique, fine-tuned, and rapidly acting pulmonary immune system to maintain homeostasis [91]. When the immunohistological expression of TNFα and its receptors was evaluated in healthy human lung tissue, TNFα was shown to be particularly prominent in bronchial epithelial cells, vascular smooth muscle cells, and alveolar macrophages. In addition, TNFR1 was shown to be eminently expressed on bronchial epithelial cells and endothelial cells, while TNFR2 was expressed by nearly all cell types [92]. Therefore, it is not surprising that in the complex process of lung cancer onset, progression, and dissemination, TNFα and its receptors have been reported to play decisive roles, too. Indeed, it was recently described that TNF is one of the co-occurring frequently altered immune genes found within the TCGA pan-cancer lung adenocarcinoma (LUAD) dataset (n = 507) [93]. However, the exact effect seems to be nuanced by contradicting functions governed by their isoforms, signal strength, and downstream signaling pathways. This is illustrated by the finding that specific genetic polymorphisms of the TNF gene region impact lung cancer progression differently. While the 238 G > A polymorphism, found in the promoter region of TNFα, has a favorable prognostic association for NSCLC [94], the 308 G>A polymorphism constitutes an increased risk for lung cancer [95].

Another opposing effect is found for sTNFα and tmTNFα on lung cancer growth [96]. When murine lung tumor lines expressed tmTNFα, their engraftment resulted in the formation of small tumors with reduced tumor-associated myeloid cell infiltration, in contrast to control or sTNFα-overexpressing lines. The observed myeloid cell reduction was found to be a direct effect of tmTNFα on myeloid survival via induction of ROS-mediated cell necrosis. Furthermore, human NSCLC was shown to express varying levels of sTNFα and tmTNFα, and gene expression patterns favoring tmTNFα appeared predictive of improved lung cancer survival [96]. This is in contrast with previous findings using the mammary 4T1 model and, moreover, counterintuitive, as tmTNFα shows a higher affinity than sTNFα for the immunosuppression promoting TNFR2 [87]. The fact that TNFα could have a favorable impact on survival is further supported by a study on citronellol’s ability to induce necroptosis of human lung tumor cells in vitro and in vivo. This study identified a decisive role for TNFα in this necroptosis induction via its activation of RIP1/3 and simultaneous downregulation of caspase 3/8 activity [97].

In an attempt to predict the most common interactions between the different TNFα-signaling members within the lung TME, we compared the overall TNF, TACE, TNFR1, and TNFR2 expression profiles within a healthy tissue and TCGA pan-cancer LUAD transcriptomic data set. We found a significant reduction of TNF, TACE, and TNFR2 transcripts within the LUAD cohort (Figure 2A,B), leading to an increased TNFR1/TNFFR2 ratio (Figure 2C). These findings imply that LUAD tumors are characterized by reduced
numbers of TNFα and especially of sTNFα molecules as TACE is significantly reduced. The specific reduction of TNFR2 and not TNFR1 in LUAD tumors further implies that TNFR1 but not TNFR2 plays a crucial role in tumor progression. As TNFR1 also shows high affinity for LTα3, we used the same LUAD cohort to evaluate the expression profile of the lymphotoxin alpha monomer encoding gene LTA. We found a significant upregulation of LTA in the LUAD cohort compared to healthy controls (Figure 2D). Previous studies linked the expression of at least two LTA-signaling members to a poor clinical outcome in lung cancer patients: the receptor for the heterotrimeric LTαβ (LTβR) and the alternative LTα3 receptor herpes virus entry mediator (HVEM) [98,99]. Overall, these findings suggest that the TNFα pathway will have the highest likelihood to signal within the LUAD TME via TNFR1 through low-affinity binding to tmTNFα or high-affinity binding to LTα3, as graphically visualized with green arrows in Figure 3.

![Figure 2](image-url)

**Figure 2.** Gene expression analysis of several TNF family members within lung cancer patients. (A–D) Expression profiles were collected from TCGA for both normal (n = 58) and LUAD tumor tissue (n = 488). Next, we obtained the Log2-transformed normalized RSEM values via Wanderer for TNF (A), TACE (B), TNFR1 and 2 (C), and LTA (D) [100]. For (C), the ratio of the expression values of TNFR1 over TNFR2 is depicted. Statistical analysis was performed using the Mann–Whitney test (****, p < 0.0001). (E,F) Gene expression analysis of TACE, TNFR1, and TNFR2 in CD8+ T cells from NSCLC patients before and during anti-PD-1 mAb treatment. RNAseq dataset obtained from the Gene Expression Omnibus (GEO) database (accession number: GSE111414, accessed on 06/07/2021). Counts were normalized using DESeq2 in R. Counts for TNF were zero for most samples (data not shown). (A) Gene expression profile of TACE in both non-responder and responder groups. (B) Ratio of TNFR1 and TNFR2 normalized expression values. For each group: n = 5.
In conclusion, preclinical evidence suggests that TNFR2 is involved in lung tumor progression while tmTNFα (with high affinity for TNFR2) has been linked to a better prognosis. Nevertheless, studies on the lung tumor growth promoting role of TNFα signaling are ample, too. First, several clinical studies have reported on the decisive role of TNFα in lung cancer EMT, invasion, and metastasis [101,102]. Secondly, TNFα has been shown to play an essential role in creating an immunosuppressive lung TME [103], among others, by upregulating MHC-II in alveolar type-II (AT-II) cells responsible for a plethora of functions that support the maintenance and optimal functioning of alveoli. Because AT-II cells’ primary function is not antigen presentation, they lack co-stimulatory signals (CD80/CD86), essential to effectively prime CD4+ T cells. Thus, instead of creating an antitumor immune response, increased AT-II cell-specific MHC-II expression can trigger Treg differentiation [104]. Numerous studies evaluated TNFR2 as a potential biomarker for NSCLC as it has been shown to be crucial for TNFα-mediated immunosuppression [105,106]. High amounts of TNFR2+ Tregs have been found in the TME of murine [39,107] as well as human advanced lung cancers [108,109], suggesting that Tregs are activated through TNFα/TNFR2 signaling. In addition, TNFR2 expression by lung tumor cells and the lung TME has been shown to support tumor cell survival [110], pre-metastatic niche formation [111], and neovascularization via vascular endothelial growth factor (VEGF) release. These findings are further supported by the observation that the levels of TNFR2 expression in human lung cancer patients, which are up to 35% [106], correlate positively to a more advanced clinical stage, immune invasion, progressive metastasis, shorter survival time, and poor prognosis [106,108]. These findings were confirmed in TNFR2-ko mice engrafted with the Lewis lung carcinoma (LLC) model. Compared to wild type and TNFR1/2 double ko mice, tumor growth decreased twofold in TNFR2-ko mice specifically and correlated with reduced VEGF expression and capillary density, along with increased numbers of apoptotic LLC cells. As they further showed that blocking TNFR2 via a short-hairpin RNA in cultured LLCs increased TNFα-mediated apoptosis and expression of several angiogenic factors, they confirmed that TNFR2 directly ameliorates angiogenesis and LLC survival [110]. Moreover, Chopra et al. reported that TNFα or TNFR2 deficiency on immune cells resulted in the reduction of lung metastasis and a decrease in the number of pulmonary Tregs [39].

In conclusion, preclinical evidence suggests that TNFR2 is involved in lung tumor progression while tmTNFα (with high affinity for TNFR2) has been linked to a better

Figure 3. Overview of TNFα signaling within LUAD with link to prognosis and checkpoint inhibition. (+) low-affinity binding, green arrows support likeliness of TNFα-signaling pathways in LUAD patients. This figure was created with BioRender.com (accessed on 5 August 2021).
prognosis for lung cancer patients. This implies that the biomarker potential of tmTNFα and TNFR2 for lung cancer progression most likely pivots on the delicate balances of sTNFα over tmTNFα as well as TNFR1 over TNFR2.

4. Linking TNFα to Antitumor Immunotherapy in Lung Cancer

The goal of antitumor immunotherapy is to completely and specifically eradicate both primary and metastatic tumor lesions by mobilized cytotoxic effector cells. Hence, immunotherapy can achieve actual cures of advanced lung cancer patients, representing an unprecedented reality [112,113]. Therefore, the first FDA approval of an immunotherapeutic treatment for squamous cell NSCLC benchmarked a revolutionary era for lung cancer patients. This treatment is based on blocking the immune checkpoint programmed death-1 (PD-1) pathway. Under healthy conditions this pathway is used to put an adequate brake on T cell stimulation and return to homeostatic conditions. As tumor cells can express the PD-1 ligand (PD-L1) themselves, they can corrupt this pathway to hinder their execution by PD-1+ TAA-specific cytotoxic effector cells [114,115]. Since 2016, five PD-(L)1 inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab, and cemiplimab) have been approved by the FDA as second- and/or first-line treatment options for advanced NSCLC [93]. Notably, for the treatment of SCLC, both nivolumab and pembrolizumab were originally approved [116] yet have been withdrawn from the US market since confirmatory trials failed to evidence improved survival outcomes. Additionally, only ~20% of unselected NSCLC patients benefit from blocking immune checkpoints, and many of the initial responders eventually develop resistance to therapy. Moreover, the growing trend to combine several immune checkpoint inhibitors (ICIs) coincides with a growing occurrence of severe to fatal immune-related adverse effects (irAEs), often related to a local increase in TNFα [117]. Together with the emerging concept of hyperprogression upon ICI [118], these phenomena cast light on the current knowledge gap of immunotherapy hampering mechanisms.

In search for clues, the relationship between TNFα and immune checkpoint signaling in the TME is being explored, hinting towards a lead role for TAMs. While IFN-γ is the main regulator of PD-L1 expression in tumor cells, PD-L1 expression in TAMs seems to be regulated via TNFα [119]. In 2017, Hartley et al. demonstrated that TNFα increases the expression of PD-L1 on bone marrow-derived monocytes and macrophages. They found that this was maintained through the secretion of versican by tumor cells, which stimulated the production of TNFα by monocytes themselves in a TLR2-dependent manner [120]. One year later, the same group provided more evidence on the interactions between the TNFα and PD-L1 pathways, as they demonstrated that PD-L1 blockade increased spontaneous macrophage proliferation, survival, and activation in vitro. Via RNAseq and IPA software analysis of these anti-PD-L1 treated macrophages, they further revealed an activated TNFR2 signaling profile [119]. Furthermore, it was recently shown in NSCLC patients that TNFα-secreting TAMs can enhance hypoxia and aerobic glycolysis and that TAMs dampen PD-L1 expression on murine lung tumor cells specifically [121,122]. The latter does contradict the observation that TAM-secreted TNFα could stabilize PD-L1 expression on 4T1 mammary cancer cells, triggering immunosuppression in vivo [123].

As melanoma remains the textbook example for immunotherapy responsiveness, TNFα targeting studies are most numerous for this cancer type. Overall, preclinical TNFα blockade has been shown to reduce the induction of irAEs upon ICI combinations and even improve therapeutic effectiveness of ICIs [117,124]. Upon adoptive CD8+ T cell transfer, TNFα appeared to be a crucial factor in the incitement of melanoma dedifferentiation, which resulted in immune escape and melanoma relapse [125]. Bertrand et al. partly explained these effects by the observation that TNFα/TNFRI signaling triggers AICD of tumor-infiltrating CD8+ T cells in melanoma, with subsequent lack of response to anti-PD-1 therapy [126]. Hence, via systemic administration of etanercept, melanoma growth was inhibited in immunocompetent animals specifically. Notably, similar effects were seen in TNFR1-ko, but not TNFR2-ko, mice, suggestive for the decisive role of TNFRI in
this AICD of CD8+ T cells [127]. A few years later, Bertrand et al. further validated these findings by showing that anti-PD-1 therapy can stimulate T-cell expression of the alternative checkpoint T-cell immunoglobulin and mucin domain 3 (TIM-3) via TNFx. Moreover, they could demonstrate that co-blockade of PD-1 and TNFx overcomes resistance to anti-PD-1 monotherapy [124]. Hence, we eagerly await the results from the first Phase Ib, open-label trial [128] that is evaluating the administration of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in combination with the anti-TNFx drug infliximab or certolizumab in patients with advanced melanoma.

In contrast to melanoma, only a handful of preclinical studies have explored the potential of TNFx pathway modulating strategies to treat lung cancer with rather contradictory findings. For example, anti-TNFx antibody treatment has been tested together with an intrapulmonary IFN-beta immuno-gene therapy (Ad.IFNβ) in an orthotopic mouse model of lung cancer. The rationale for this was that blocking the pro-inflammatory actions of TNFx could reduce the induction of dose-limiting pulmonary inflammation upon Ad.IFNβ delivery. However, upon administration, the anti-TNFx antibody not only significantly reduced the pulmonary inflammation but also the therapeutic effect of Ad.IFNβ delivery. Hence, TNFx proved to be both a dose-limiting factor as well as crucial for the anti-tumor immune stimulatory capacity of Ad.IFNβ [129]. More straightforward was the negative role described for TNFα secretion by TAMs, as this promoted cell glycolysis, tumor hypoxia, and decreased PD-L1 expression. Hence, when the TNFα-secreting TAMs were depleted upon clodronate treatment of LLC-engrafted mice, PD-L1 expression significantly increased in the aerobic cancer cells. Moreover, this treatment increased tumor T cell infiltration and most importantly, its response to anti-PD-L1 therapy, which was otherwise completely ineffective [121]. While the above study suggests that TNFx blockade can increase effectivity of anti-PD-L1 therapy, this seems diametrically opposed to the observation that not reduced but increased serological levels of TNFx were found to be associated with improved anti-PD-1 treatment response and survival in NSCLC (along with IFN-γ, IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12) [130]. Using an online available RNAseq dataset on CD8+ T cells sorted out of NSCLC patients’ peripheral blood mononuclear cells before and during anti-PD-1 mAb therapy [131], we were able to support the notion that increased levels of sTNFα could be linked to improved anti-PD-1 treatment response, as we found a non-significant increase in TACE expression within the responder group specifically, linked to more release of sTNFα from its tmTNFα form (Figure 2E). While the TNFR1/TNFR2 ratio decreased upon anti-PD-1 treatment, this phenomenon was seen in both the responder and non-responder groups (Figure 2F). Finally, the levels of LTA were very similar between the responder and non-responder groups (data not shown), although we were unable to draw any conclusions for TNF due to the lack of representative data, underscoring the current lack of human data on gene expression profiles of the different TNFα family members before, during, and after antitumor immunotherapy.

5. Conclusions and Future Perspectives on TNFα Modulation for Lung Cancer Treatment

The multitude of contradictory findings currently poses a stalemate for TNFx pathway-affecting strategies in combination with immunotherapy to treat lung cancer and suggests the need for additional research into biomarkers to guide rationalized therapy combinations. This conundrum is reflected by the range of preclinical studies that report on the therapeutic efficacy of TNFα upon its administration as well as its inhibition [132]. To illustrate, when a TNF-based Activity-on-Target cytokine (AcTakine) was specifically targeted to the CD13+ neovasculature in vivo, the rapid destruction of the tumor neovasculation and complete regression of large, established tumors was demonstrated. In contrast, selective blockage of sTNFα via INB03 led to a reduced carcinogen-induced tumor incidence and growth rate [133]. Moreover, a detrimental role has been attributed to sTNFα and TNFR1 for melanoma-infiltrated functional CD8+ T cells as well as the onset of irAEs, rationalizing combined TNFα-blockade with immunotherapy to treat melanoma.
By mining existing next-generation sequencing data from LUAD patients, the latter were shown to contain less TNF, and because of the significant reduction in TACE, sTNFα protein is likely to be most decreased. Together with the notion that tmTNFα, and not sTNFα, has been shown to play a key role in Th1-polarized antitumor immunity and improved lung cancer patient survival [18,134], this argues against a tumor promoting role for TNFα in lung cancer, discouraging TNFα-blockage for lung cancer treatment today. Additionally, the role of TNFR2 in lung cancer progression remains undefined and requires more research. High amounts of TNFR2+ Tregs have been found in the TME of human advanced lung cancers, and TNFR2 has recently been identified as a tumor-promoting oncogene with new biomarker potential for cancer [135,136]. However, upon mining the currently available transcriptomic dataset from a TCGA LUAD patient cohort, we demonstrated that the expression of TNFR2 is markedly decreased in the lung TME. Moreover, pre-clinically, TNFR2 agonists as well as antagonists have been linked to antitumoral effects, arguing against the effectiveness of TNFR2 modulation for lung cancer therapy [137–140].

To conclude, numerous studies point out that TNFα signaling is extensively involved in lung tumor progression and response to (immuno-)therapy. However, the underlying mechanisms of the different TNFα family members that modulate tumor prognosis and response to treatment remain to be revealed. We summarized our main findings in Figure 3 to highlight that TNFα signaling involves different ligands and receptors in LUAD, which have been linked to prognosis response to PD-(L)1 treatment. To make matters more complicated, all of these components can be expressed, secreted, and sensed by a broad range of malignant, immune, and non-immune cells within the respiratory tract, whereas most (pre-)clinical data have been based on serological values of sTNFα and RNA sequencing data. Therefore, we believe that larger genomic, transcriptomic, and proteomic dataset analysis studies are needed for various disease stages and treatment options on the single cell lung TME level to advance our current understanding of the biomarker and modulatory potential of the TNFα pathway for lung cancer prognosis and therapy.

**Funding:** K.D.R. and C. Goyvaerts were supported by Kom op tegen Kanker, Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen, Wetenschappelijk Fonds Willy Gepts, and the BCLAS Fund in honor of Jean René Maisin.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Carswell, E.A.; Old, L.J.; Kassel, R.L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci. USA* **1975**, *72*, 3666. [CrossRef]
2. Aggarwal, B.B.; Gupta, S.C.; Kim, J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood* **2012**, *119*, 651. [CrossRef]
3. Baeyens, K.J.; de Bondt, H.L.; Raeymaekers, A.; Fiers, W.; de Ranter, C.J. IUCr the structure of mouse tumour-necrosis factor at 1.4 Å resolution: Towards modulation of its -selectivity and trimerization. *Acta Crystallogr.*, **1999**, *55*, 772–778. [CrossRef]
4. Schall, T.J.; Lewis, M.; Koller, K.J.; Lee, A.; Rice, G.C.; Wong, G.H.W.; Gatanaga, T.; Granger, G.A.; Lentz, R.; Raab, H.; et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. *Cell* **1990**, *61*, 361–370. [CrossRef]
5. Loetscher, H.; Pan, Y.-C.E.; Lahm, H.-W.; Gentz, R.; Brockhaus, M.; Tabuchi, H.; Lesslauer, W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. *Cell* **1990**, *61*, 351–359. [CrossRef]
6. Parameswaran, N.; Patial, S. Tumor necrosis factor-alpha signaling in macrophages. *Crit. Rev. Eukaryot. Gene Expr.* **2010**, *20*, 87–103. [CrossRef]
7. Bradley, J. TNF-mediated inflammatory disease. *J. Pathol.* **2008**, *214*, 149–160. [CrossRef]
8. Mehta, A.K.; Gracias, D.T.; Croft, M. TNF activity and t cells. *Cytokine* **2018**, *101*, 14. [CrossRef]
9. Armstrong, L.; Thickett, D.R.; Christie, S.J.; Kendall, H.; Millar, A.B. Increased expression of functionally active membrane-associated tumor necrosis factor in acute respiratory distress syndrome. *Am. J. Respir. Cell Mol. Biol.* **2012**, *46*, 68–74. [CrossRef]
10. Williams, M.A.; Newland, A.C.; Kelsey, S.M. Cytokine modulated cell-membrane bound tumour necrosis factor expression is associated with enhanced monocyte-mediated killing of human leukaemic targets. *Leuk. Res.* **2000**, *24*, 317–330. [CrossRef]
11. Horiuchi, T.; Morita, C.; Tsukamoto, H.; Mitoana, H.; Sawabe, T.; Harashima, S.-I.; Kashiwagi, Y.; Okamura, S. Increased expression of membrane tumor necrosis factor alpha on activated peripheral CD8+ T cells in systemic lupus erythematosus. *Int. J. Mol. Med.* **2006**, *17*, 875–879. [CrossRef]
12. Caron, G.; Delneste, Y.; Aubry, J.-P.; Magistrelli, G.; Herbulot, N.; Blaecke, A.; Meager, A.; Bonnefoy, J.-Y.; Jeannin, P. Human NK cells constitutively express membrane mtnf-α (mtnfα) and present mtnfα-dependent cytotoxic activity. *Eur. J. Immunol.* 1999, 29, 3588–3595. [CrossRef]

13. Xu, H.; Sethi, J.K.; Hotamisligil, G.S. Transmembrane tumor necrosis factor (TNF-α) inhibits adipocyte differentiation by selectively activating mtnfα receptor 1. *J. Biol. Chem.* 1999, 274, 26287–26295. [CrossRef]

14. Qu, Y.; Zhao, G.; Li, H. Forward and reverse signaling mediated by transmembrane tumor necrosis factor-alpha and mtnfr receptor 2: Potential roles in an immunosuppressive tumor microenvironment. *Front. Immunol.* 2017, 8, 1675. [CrossRef] [PubMed]

15. Caldwell, A.B.; Cheng, Z.; Vargas, J.D.; Birnbaum, H.A.; Hoffmann, A. Network Dynamics determine the autocrine and paracrine signaling functions of TNF. *Genes Dev.* 2014, 28, 2120–2133. [CrossRef] [PubMed]

16. FionnulaM, B.; Jackson, A.; Chantry, D.; Maint, R.; Feldmann, M. Inhibitory effect of mtnf alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. *Lancet* 1989, 334, 244–247. [CrossRef]

17. Mariano, M.W.; Dunn, A.; Grail, D.; Inglese, M.; Noguchi, Y.; Richards, E.; Jungbluth, A.; Wada, H.; Moore, M.; Williamson, B.; et al. Characterization of tumor necrosis factor-deficient mice. *Proc. Natl. Acad. Sci. USA* 1997, 94, 8093–8098. [CrossRef]

18. Xu, J.; Chakrabarti, A.K.; Tan, J.L.; Ge, L.; Gambotto, A.; Vujanovic, N.L. Essential role of the TNF-TNFR2 cognate interaction in the differentiation and function of CD4+ Foxp3+ induced treg cells in vitro and in vivo periphery in auto. *Cell Death Dis.* 2017, 8, e31. [CrossRef] [PubMed]

19. Horiuchi, T.; Mitoma, H.; Harashima, S.; Tsukamoto, H.; Shimoda, T. Transmembrane TNF-α: Structure, function and interaction with anti-mtnf agents. *Rheumatology* 2007, 109, 3333–3341. [CrossRef]

20. Parry, S.L.; Sebbag, M.; Feldmann, M.; Brennan, F.M. Contact with T cells modulates monocyte il-10 production: Role of T cell membrane TNF-α. *J. Immunol.* 1997, 158, 3673–3681.

21. Rossol, M.; Meusch, U.; Pierer, M.; Kaltenhäuser, S.; Häntzschel, H.; Hauschildt, S.; Wagner, U. Interaction between trans-membrane mtnf and mtnfr1/2 mediates the activation of monocytes by contact with T cells. *J. Immunol.* 2007, 179, 4239–4248. [CrossRef]

22. Eissner, G.; Kolch, W.; Scheurich, P. Ligands working as receptors: Reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. *Cytokine Growth Factor Rev.* 2004, 15, 353–366. [CrossRef]

23. Deng, J.; Zhao, X.; Rong, L.; Li, X.; Liu, X.; Qin, Z. TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy. *Protein Cell* 2013, 4, 393. [CrossRef]

24. Zhao, Y.; Yang, F.; Li, W.; Xu, C.; Li, L.; Chen, L.; Liu, Y.; Sun, P. MiR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. *Tumor Biol.* 2017, 39, 1010428317692264. [CrossRef]

25. Yang, Z.; Wang, Y.; Zhang, L.; Zhao, C.; Wang, D. Phosphorylated form of pyruvate dehydrogenase α mediates tumor necrosis factor α induced glioma cell migration. *Oncol. Lett.* 2021, 21, 176. [CrossRef]

26. Hwang, H.S.; Park, Y.-Y.; Shin, S.-J.; Go, H.; Park, J.-M.; Yoon, S.Y.; Lee, J.-L.; Cho, Y.M. Involvement of the TNF-α pathway in TKI resistance and suggestion of TNFR1 as a predictive biomarker for TKI responsiveness in clear cell renal cell carcinoma. *J. Korean Med. Sci.* 2020, 35, e31. [CrossRef] [PubMed]

27. Huang, P.; Rani, M.R.S.; Ahluwalia, M.S.; Bae, E.; Prayson, R.A.; Weil, R.J.; Nowacki, A.S.; Hedayat, H.; Sloan, A.E.; Lathia, J.D.; et al. Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin A6β1 in glioblastoma. *Cancer Res.* 2012, 72, 1428–1437. [CrossRef] [PubMed]

28. Wajant, H.; Siegmund, D. TNFR1 and TNFR2 in the control of the life and death balance of macrophages. *Front. Cell Dev. Biol.* 2019, 7, 91. [CrossRef] [PubMed]

29. Polz, J.; Remke, A.; Weber, S.; Schmidt, D.; Weber-Steifens, D.; Pietryga-Krieger, A.; Müller, N.; Ritter, U.; Mostböck, S.; Männel, D.N. Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. *Immun. Inflammm. Dis.* 2014, 2, 121–130. [CrossRef] [PubMed]

30. Faustman, D.; Davis, M. TNF receptor 2 pathway: Drug target for autoimmune diseases. *Nat. Rev. Drug Discov.* 2010, 9, 482–493. [CrossRef] [PubMed]

31. Grell, M.; Wajant, H.; Zimmermann, G.; Scheurich, P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. *Proc. Natl. Acad. Sci. USA* 1998, 95, 570–575. [CrossRef]

32. Grell, M.; Douni, E.; Wajant, H.; Löhden, M.; Clauss, M.; Maxeiner, B.; Scheurich, P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell* 1995, 83, 793–802. [CrossRef]

33. Ding, X.; Yang, W.; Shi, X.; Du, P.; Su, L.; Qin, Z.; Chen, J.; Deng, H. TNF receptor 1 mediates dendritic cell maturation and CD8 T cell response through two distinct mechanisms. *J. Immunol.* 2011, 187, 1184–1191. [CrossRef]

34. Yang, S.; Xie, C.; Chen, Y.; Wang, J.; Chen, X.; Lu, Z.; June, R.R.; Zheng, S.G. Differential roles of TNFα-TNFFR1 and TNFα-TNFFR2 in the differentiation and function of CD4 + Foxp3 + induced treg cells in vitro and in vivo periphery in auto. *Cell Death Dis.* 2019, 10, 27. [CrossRef] [PubMed]

35. Almishri, W.; Santodomingo-Garzon, T.; Le, T.; Stack, D.; Mody, C.H.; Swain, M.G. TNFα Augments cytokine-induced NK cell IFNγ production through TNFR2. *J. Innate Immun.* 2016, 8, 617–629. [CrossRef]

36. Zheng, L.; Fisher, G.; Miller, R.E.; Peschon, J.; Lynch, D.H.; Lenardo, M.J. Induction of apoptosis in mature T cells by tumour necrosis factor. *Nature* 1995, 377, 348–351. [CrossRef]

37. Chen, X.; Bäumel, M.; Männel, D.N.; Howard, O.M.Z.; Oppenheim, J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. *J. Immunol.* 2007, 179, 154–161. [CrossRef] [PubMed]
/Int. J. Mol. Sci. 2021, 22, 8691

64. Fräter-Schröder, M.; Risau, W.; Hallmann, R.; Gautschi, P.; Böhlen, P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA 1987, 84, 5277. [CrossRef]
65. Sainson, R.C.A.; Johnston, D.A.; Chu, H.C.; Holderfield, M.T.; Nakatsu, M.N.; Crampton, S.P.; Davis, J.; Conn, E.; Hughes, C.C.W. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 2008, 111, 4997–5007. [CrossRef]
66. Giraudo, E.; Primo, L.; Audero, E.; Gerber, H.-P.; Koolwijk, P.; Soker, S.; Klagsbrun, M.; Ferrara, N.; Bussolino, F. Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J. Biol. Chem. 1998, 273, 22128–22135. [CrossRef]
67. Patterson, C.; Ferrella, M.A.; Endege, W.O.; Yoshizumi, M.; Lee, M.E.; Haber, E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Investig. 1996, 98, 490. [CrossRef]
68. Fajardo, L.; Kwan, H.; Kowalski, J.; Prionas, D.; Allison, A. Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 1992, 140, 539–544.
69. Gina, L.; Tonya, C.W.; Steven, M.D. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr. Opin. Pulm. Med. 2009, 15, 303–307. [CrossRef]
70. Greten, F.R.; Grivennikov, S.I. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 2019, 51, 27–41. [CrossRef]
71. Yan, B.; Wang, H.; Rabbani, Z.N.; Zhao, Y.; Li, W.; Yuan, Y.; Li, F.; Dewhirst, M.W.; Li, C.-Y. Tumor necrosis factor-α primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 2008, 111, 4997–5007. [CrossRef]
72. Grivennikov, S.I. Inflammation and colorectal cancer: Colitis-associated neoplasia. Semin. Immunopathol. 2012, 35, 229–244. [CrossRef]
73. Suarez-Carmona, M.; Lesage, J.; Cataldo, D.; Gilles, C. EMT and inflammation: Inseparable actors of cancer progression. Mol. Oncol. 2017, 11, 805–823. [CrossRef] [PubMed]
74. Balkwill, F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25, 409–416. [CrossRef] [PubMed]
75. Gaur, U.; Aggarwal, B.B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 2003, 66, 1403–1408. [CrossRef]
76. Idriss, T.H.; Naismith, H. James TNFα counterbalances the emergence of M2 tumor macrophages. Cancer Res. 2013, 73, 409–416. [CrossRef]
77. Huang, Y.; Yu, X.; Wang, L.; Zhou, S.; Sun, J.; Feng, N.; Nie, S.; Wu, J.; Gao, F.; Fei, B.; et al. Four genetic polymorphisms of lymphoxygen-alpha gene and cancer risk: A systematic review and meta-analysis. PLoS ONE 2013, 8, e82519. [CrossRef]
78. Vesely, M.D.; Schreiber, R.D. Cancer immunoeediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 2013, 1284, 1–5. [CrossRef] [PubMed]
79. McCoach, C.E.; Bivona, T.G. The evolving understanding of immunoeediting and the clinical impact of immune escape. J. Thorac. Dis. 2018, 10, 12482–1252. [CrossRef] [PubMed]
80. Mittal, D.; Gubin, M.M.; Schreiber, R.D.; Smyth, M.J. New insights into cancer immunoeediting and its three component phases—elimination, equilibrium and escape. Curr. Opin. Immunol. 2014, 27, 16–25. [CrossRef] [PubMed]
81. Kratovitch, F.; Neale, G.; Haverkamp, J.M.; Van de Velde, L.-A.; Smith, A.M.; Kawachi, D.; McEvoy, J.; Roussel, M.D.; Fyer, M.A.; Qualls, J.E.; et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015, 12, 1902–1914. [CrossRef]
82. Braunmüller, H.; Wieder, T.; Brenner, E.; Aßmann, S.; Hahn, M.; Alkhaled, M.; Crampton, S.P.; Davis, J.; Conn, E.; Hughes, C.C.W.; Qualls, J.E.; et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015, 12, 1902–1914. [CrossRef]
83. Müller-Hermelink, N.; Braunmüller, H.; Pichler, B.; Wieder, T.; Mailhammer, R.; Schaak, K.; Goreschi, K.; Yazdi, A.; Haubner, B.; Rander, S.; Curr. Op. Immunol. 2013, 25, 361–365. [CrossRef]
84. Schioppa, T.; Moore, R.; Thompson, R.G.; Rossor, E.C.; Kulbe, H.; Nedospasov, S.; Mauri, C.; Coussens, L.M.; Balkwill, F.R. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 10662–10667. [CrossRef]
85. Zhao, X.; Rong, L.; Zhao, X.; Lin, G.; Wang, M.; Wang, J.; Jiang, X.; Feng, W.; et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J. Immunol. 2014, 192, 1320–1331. [CrossRef]
86. Sayed, M.F.A.; Amrein, M.A.; Bührer, E.D.; Huguenin, A.-L.; Bucur, R.; Riether, C.; Ochsenbein, A.F. T-cell–secreted TNF drives myeloid and myeloid-derived suppressor cell differentiation in cancer. Cancer Res. 2019, 79, 346–359. [CrossRef]
87. Hu, X.; Li, B.; Li, X.; Zhao, X.; Wan, L.; Lin, G.; Yu, M.; Wang, J.; Jiang, X.; Feng, W.; et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J. Immunol. 2014, 192, 1320–1331. [CrossRef]
88. Liu, Y.; Ji, X.; Kang, N.; Zhou, J.; Liang, X.; Li, J.; Han, T.; Zhao, C.; Yang, T. Tumor necrosis factor-α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer. Cell Death Dis. 2020, 11, 1–13. [CrossRef]
89. Lung Statistics, Globocan, Number of New Cases. 2020. Available online: https://Gco.Iarc.Fr/Today/Data/Factsheets/Cancers/15-Lung-Fact-Sheet.Pdf (accessed on 1 July 2021).
90. Travis, W.D.; Brambilla, E.; Nicholson, A.G.; Yatabe, Y.; Austin, J.H.M.; Beasley, M.B.; Chirieac, L.R.; Dacic, S.; Duhig, E.; Flieder, D.B.; et al. The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. *J. Thorac. Oncol.* 2015, 10, 1243–1260. [CrossRef] [PubMed]

91. Hartl, D.; Tirovanziam, R.; Laval, J.; Greene, C.M.; Habel, D.; Sharma, L.; Yildirim, A.O.; Dela Cruz, C.S.; Hogaboam, C.M. Innate immunity of the lung: From basic mechanisms to translational medicine. *J. Innate Immun.* 2018, 10, 487–501. [CrossRef] [PubMed]

92. Ermert, M.; Pantazis, C.; Duncker, H.R.; Grimminger, F.; Seeger, W.; Ermert, L. In situ localization of TNFα/β, tace and TNF Receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. *Cytokine* 2003, 22, 89–100. [CrossRef]

93. Shih, C.-M.; Lee, Y.-L.; Chou, H.-L.; Chen, W.; Chang, G.-C.; Chou, M.-C.; Lin, L.-Y. Association of TNF-α polymorphism with susceptibility to and severity of non-small cell lung cancer. *Lung Cancer* 2006, 52, 15–20. [CrossRef] [PubMed]

94. Spella, M.; Stathopoulos, C.T. Immune resistance in lung adenocarcinoma. *Cancers* 2021, 13, 384. [CrossRef]

95. Xie, H.; Yao, H.; Huo, Y.; Li, N.; Cheng, Y. Association between TNF-α gene 308G>A polymorphism and lung cancer risk: A meta-analysis. *Tumor Biol.* 2014, 35, 9693–9699. [CrossRef]

96. Ardestani, S.; Li, B.; Deskins, D.L.; Wu, H.; Massion, P.P.; Young, P.P. Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. *Cancer Res.* 2013, 73, 3938–3950. [CrossRef]

97. Yu, W.-N.; Lai, Y.-J.; Ma, J.-W.; Ho, C.-T.; Hung, S.-W.; Chen, Y.-H.; Chen, C.-T.; Kao, J.-Y.; Way, T.-D. Citronellol induces necroptosis of human lung cancer cells via TNFα pathway and reactive oxygen species accumulation. *In Vivo* 2019, 33, 1193–1201. [CrossRef] [PubMed]

98. Dimitrakopoulos, F.-I.D.; Kottorou, A.E.; Antonacopoulou, A.G.; Panagopoulos, N.; Scopa, C.; Kalofonou, M.; Dougenis, D.; Koutras, A.; Makatsoris, T.; Tzelepi, V.; et al. Expression of immune system-related membrane receptors CD40, RANK, BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients. *J. Clin. Med.* 2019, 8, 741. [CrossRef]

99. Ren, S.; Tian, Q.; Amar, N.; Yu, H.; Rivard, C.J.; Caldwell, C.; Ng, T.L.; Tu, M.; Liu, Y.; Gao, D.; et al. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. *Lung Cancer* 2018, 125, 115–120. [CrossRef] [PubMed]

100. Díez-Villanueva, A.; Mallona, I.; Peinado, M.A. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. *Epigenetics Chromatin* 2015, 8, 1–8. [CrossRef] [PubMed]

101. Shang, G.-S.; Liu, L.; Qin, Y.-W. IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition. *Oncol. Lett.* 2017, 13, 4657. [CrossRef] [PubMed]

102. Chae, Y.; Chang, S.; Ko, T.; Anker, J.; Agte, S.; Iams, W.; Choi, W.; Lee, K.; Cruz, M. Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). *Sci. Rep.* 2018, 8. [CrossRef]

103. Gong, L.; Caetano, M.D.S.; Cumpian, A.M.; Daliri, S.; Flores, A.G.; Chang, S.H.; Ochoa, C.E.; Evans, C.M.; Yu, Z.; Moghadam, S.J. Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment. *Oncoimmunology* 2016, 5, e1229724. [CrossRef]

104. Guo, N.; Wen, Y.; Wang, C.; Kang, L.; Wang, X.; Liu, X.; Soulika, A.M.; Liu, B.; Zhao, M.; Han, X.; et al. Lung adenocarcinoma-related TNF-α-dependent inflammation upregulates MHC-II on alveolar type II cells through CXCR-2 to contribute to treg expansion. *FASEB J.* 2020, 34, 12197–12213. [CrossRef]

105. Yang, Y.; Islam, M.S.; Hu, Y.; Chen, T.NFWR: Role in cancer immunology and immunotherapy. *ImmuNo Targets Ther.* 2021, 10, 103–122. [CrossRef] [PubMed]

106. Zhang, Y.W.; Chen, Q.Q.; Cao, J.; Xu, L.Q.; Tang, X.; Wang, J.; Zhang, J.; Dong, L.X. Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker. *Thorac. Cancer* 2019, 10, 437. [CrossRef]

107. Chen, X.; Subleski, J.J.; Kopf, H.; Howard, O.M.Z.; Männel, D.N.; Oppenheim, J.J. Cutting edge: Expression of TNFR2 defines a maximally suppressive subset of mouse CD4+ CD25+ FoxP3+ T regulatory cells: Applicability to tumor-infiltrating t regulatory Cells. *J. Immunol.* 2008, 180, 6467–6471. [CrossRef]

108. Yan, F.; Du, R.; Wei, F.; Zhao, H.; Yu, J.; Wang, C.; Zhan, Z.; Ding, T.; Ren, X.; Chen, X.; et al. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. *Cancer Immunol. Immunother.* 2015, 64, 1475–1485. [CrossRef]

109. Williams, G.S.; Mistry, B.; Guillard, S.; Ulrichsen, J.C.; Sandecock, A.M.; Wang, J.; Gonzalez-Muñoz, A.; Parmentier, J.; Black, C.; Soden, J.; et al. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. *Oncotarget* 2016, 7, 68278–68291. [CrossRef]

110. Sasi, S.P.; Bae, S.; Song, J.; Pereplichchikov, A.; Schneider, D.; Carrozza, J.; Yan, X.; Kishore, R.; Enderling, H.; Goukassian, D.A. Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-P75 knockdown lewis lung carcinoma tumor Implants. *PLoS ONE* 2014, 9, 9237. [CrossRef]

111. Ham, B.; Wang, N.; D’Costa, Z.; Fernandez, M.C.; Bourdeau, F.; Auguste, P.; Illenmann, M.; Efsen, R.L.; Hayer-Hansen, G.; Vainier, B.; et al. TNF receptor-2 facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases. *Cancer Res.* 2015, 75, 5235–5247. [CrossRef]

112. Remon, J.; Passiglia, F.; Ahn, M.J.; Barlesi, F.; Forde, P.M.; Garon, E.B.; Gettinger, S.; Goldberg, S.B.; Herbst, R.S.; Horn, L.; et al. Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. *J. Thorac. Oncol.* 2020, 15, 914–947. [CrossRef]
136. Sheng, Y.; Li, F.; Qin, Z. TNF receptor 2 makes tumor necrosis factor a friend of tumors. *Front. Immunol.* 2018, 9, 1170. [CrossRef] [PubMed]

137. Fischer, R.; Kontermann, R.E.; Pfizenmaier, K. Selective targeting of TNF receptors as a novel therapeutic approach. *Front. Cell Dev. Biol.* 2020, 8, 401. [CrossRef] [PubMed]

138. Torrey, H.; Butterworth, J.; Mera, T.; Okubo, Y.; Wang, L.; Baum, D.; Defusco, A.; Plager, S.; Warden, S.; Huang, D.; et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated tregs. *Sci. Signal.* 2017, 10, 462. [CrossRef]

139. Torrey, H.; Kühtreiber, W.M.; Okubo, Y.; Tran, L.; Case, K.; Zheng, H.; Vanamee, E.; Faustman, D.L. A novel TNFR2 agonist antibody expands highly potent regulatory T cells. *Sci. Signal.* 2020, 13, 661. [CrossRef]

140. Tam, E.M.; Fulton, R.B.; Sampson, J.F.; Muda, M.; Camblin, A.; Richards, J.; Koshkaryev, A.; Tang, J.; Kurella, V.; Jiao, Y.; et al. Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. *Sci. Transl. Med.* 2019, 11, 512. [CrossRef]